Search
Larimar Therapeutics Inc
LRMRAdd to Watchlist
3.640USD
+0.100+2.82%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
378.13MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Larimar Therapeutics Inc is 9.20, ranking 8 out of 389 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 26.00 and a low of 7.00.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
15.875
Target Price
+336.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Larimar Therapeutics Inc
LRMR
10
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Larimar Therapeutics Inc's price target?
Analysts forecast that Larimar Therapeutics Inc's price target is USD 18.00, with the highest forecast at USD 26.00 and the lowest forecast at USD 7.00.
How have Larimar Therapeutics IncLRMR's recent earnings per share performed?
The market expectation was USD -0.33, while Larimar Therapeutics IncLRMR's earnings per share (EPS) for the previous quarter was USD -0.73. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Larimar Therapeutics Inc?
Based on the ratings of Larimar Therapeutics Inc's stock from 10 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
